Sanguine Expands Oncology Biospecimen Offerings Through Strategic Clinic Partnerships
The Californer/10326474

SAN DIEGO, Sept. 16, 2025 ~ Sanguine Biosciences, a leading provider of healthy and disease-state human biospecimens and data for research, has announced the expansion of its oncology sample offerings through new partnerships with oncology clinics nationwide. This move is expected to provide researchers with a broader range of high-quality, minimally invasive biospecimens, including treatment-naive samples critical for advancing cancer discovery and precision medicine.

The company's partnerships with these clinics will allow Sanguine to offer researchers access to a growing inventory of oncology biospecimens, including blood, plasma, serum, and peripheral blood mononuclear cells (PBMCs). These samples are collected using minimally invasive methods in order to reduce donor burden and accelerate study timelines. Treatment-naive samples, in particular, are highly valuable as they provide rare insights into early disease biology, immune responses, biomarkers for diagnostic development, and potential therapeutic targets prior to intervention.

Sanguine's integrated technology platform plays a crucial role in streamlining data and donor engagement. By securely importing electronic medical records (EMRs) directly from clinic systems, Sanguine is able to harmonize rich clinical data with each biospecimen. This gives researchers a comprehensive and contextualized dataset. At the same time, individuals can be remotely consented into Sanguine's donor community, allowing clinics and their patients to participate in research without additional infrastructure or operational burden. This seamless integration not only accelerates access to high-quality samples and data but also preserves clinic workflows and patient experience.

More on The Californer

• First Nations Bank of Canada Partners with KYC2020 to Strengthen AML Screening and Monitoring Capabilities
• California: Governor, First Partner mark Latina Equal Pay Day, sign Pay Equity Enforcement Act
• Bitcoin will still be the leader in the cryptocurrency market in 2025, and WOA Mining enthusiasts will earn passive income
• California: El Gobernador conmemora el Día de la Igualdad Salarial para Latinas junto con la Primera Pareja, y firma la Ley de Aplicación de la Equidad Salarial
• Gen Z Is Reshaping the Accounting Profession New Podcast Episode Highlights the Future of Accounting

Gerald Lee, co-founder and Chief Product Officer at Sanguine Biosciences stated that "By leveraging our infrastructure, technology, and operations, Sanguine has partnered with over 20 oncology clinics across the United States to create a path for empowering researchers with timely access to a diverse group of highest-quality patient samples." He further added that "Our expanded oncology offerings, especially treatment-naive biospecimens, will support breakthrough studies in biomarker discovery, drug development, and personalized cancer therapies."

Sanguine's expanded oncology capabilities complement its existing nationwide donor network, advanced logistics infrastructure, and robust data integration services. This enables researchers to obtain treatment-naive oncology samples across multiple cancer types, longitudinal and minimally invasive collections to track disease progression, matched blood products including plasma, serum, and PBMCs, as well as detailed electronic medical records, clinical and demographic metadata to enhance translational insights.

With cancer research evolving rapidly, access to high-quality, clinically annotated biospecimens remains a critical bottleneck. Sanguine's latest initiative directly addresses this challenge by enabling academic institutions, biotech companies, and pharmaceutical researchers to accelerate discoveries and bring new diagnostics and therapies to patients faster.

More on The Californer

• Triumph Thru Tears Premieres at 55th Anniversary Pamoja Celebration at the University of Georgia
• Riding Into the Frontier of Freedom on Destination: Scientology, Dallas
• California: Governor Newsom signs first-in-the-nation law to ban ultra-processed foods from school lunches
• Screen Share Report: Spotlighting Diversity in Daytime Drama
• Helping Haircare Brands Launch with Confidence: Bond & Bloom Innovation Group Leads in Product Development

For more information about Sanguine's oncology biospecimen offerings or to request samples, interested parties can visit their website at www.sanguinebio.com. Sanguine Biosciences is dedicated to accelerating the adoption of personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. By merging annotated patient biospecimens with real-world and analytical data, Sanguine delivers actionable biomarker discovery and validation studies that bridge the gap between patients and scientists working on innovative therapies. The company has supported translational and clinical research at 30 of the top 40 global pharmaceutical and biotechnology companies. Additionally, for the past four years, Sanguine has received the prestigious designation as a "Great Places to Work'' company.

---

Show All News | Report Violation